Health & Biotech
PharmAust Limited (ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for human and animal health applications.
The company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs. MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently completing a Phase 1 study in patients with MND/ALS. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase 1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Tech
PharmAust leans to renewable energy, signs deal to convert waste to fuel
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
So, COVID vaccines are here; what now for all those biotechs working on COVID 19 drugs or tests?
News
Last Orders: What you might have missed on the ASX today
News
Last Orders: What you might have missed on the ASX today
Health & Biotech
Who else on the ASX joins Mesoblast in the fight against ARDS and where are they at?
Health & Biotech
Check Up: A bit of progress for the health sector
News
Weekly ASX small cap wrap: Who can’t afford to put pork on their fork this week?
Health & Biotech
Cyclopharm, AnteoTech and PharmAust report COVID-19 progress
Health & Biotech
PharmAust gets on the hunt for a new partner to develop its canine cancer treatment
News
10 at 10: These ASX stocks are a landslide this morning
Health & Biotech
SomnoMed taps tech for new board hires, posts full-year profit
Health & Biotech
How many stocks fighting COVID-19 have maintained their momentum?
News
10 at 10: These ASX stocks are casting nets this morning
News
Rise and Shine: What you need to know before the ASX opens
News
10 at 10: These ASX stocks are looking colourful this morning
News